EFFICACY AND SAFETY OF GRAZOPREVIR/ELBASVIR plus /- RBV FOR 12 WEEKS IN PATIENTS WITH HCV G1 OR G4 INFECTION WHO PREVIOUSLY FAILED PEGINTERFERON/RBV: C-EDGE TREATMENT-EXPERIENCED TRIAL - Kwo, P; Gane, E; Peng, C Y (Journal of hepatology, 2015)
et al.